Shopping Cart (0)
My Account

Shopping Cart
SELECTBIO Conferences Current Trends in Antibody Drug Conjugates

Current Trends in Antibody Drug Conjugates



Keynote Speakers


Alain Bernard
Vice President, UCB Pharma SA


Dimiter Dimitrov
Head/Senior Investigator, National Institutes of Health


Palani Palaniappan
Vice President & Head, Takeda Pharmaceuticals International Co.

Overview

SELECTBIO brings to you its inaugural International conference on ADC Development & Manufacture "Current Trends in Antibody Drug Conjugates" on March 2-3, 2015 in Sheraton Bangalore Hotel at Brigade Gateway, Bangalore.

An innovative therapeutic application which combines the distinctive properties of monoclonal antibodies (mAbs) with the potent cytotoxic effect of small drug molecules is Antibody-drug conjugates or ADCs. This conference will be covering the different aspects of ADC development and manufacture, right from the introduction to regulatory aspects thereby ensuring comprehensive understanding of the subject. In addition this event will provide an excellent platform for knowledge sharing, collaborative research and networking with the scientists in the field of Antibody Engineering, Antibody drug conjugates, biopharmaceuticals and Cancer research.

This event is co-located with our International Conference on Cell Culture and Cell based assays i.e. CellTech India 2015. Running alongside the conferences will be an exhibition covering the latest advancements in the instrumentation for antibody and cell technologies related research and development.

International Advisory Board Members

Dr. Franck Pavan, Business Development Manager, Pierre Fabre, France
Dr. Ram Upadhayaya, Head- Medicinal Chemistry, Bioimics AB, Sweden
Dr. Satish Singh, Research Fellow and Group Leader, Pfizer, USA
Dr. Vijay Upreti, Principal Scientist, Clinical Pharmacology, Modeling & Simulation , Amgen, USA
Dr. Klaus Krauser, Executive Director- Safety Assessment, Novartis, Biotherapeutics Development Unit,USA
Dr. Jagath Reddy Junutula, Vice President-Antibody Discovery & Development, Cellerant Therapeutics, Inc., USA
Dr. Andreas Pahl, Chief Scientific Officer & Executive Vice President, Heidelberg Pharma, Germany
Dr. Janet Wolfe, President and Founder, Wolfe Laboratories, USA
Dr. Anil Wagh, Scientist, Bristol-Myers Squibb, USA

Note: For details of the conference package, please contact Ms. Sakshi, s.modgil@selectbio.com; 07696125050

Agenda Topics

  • ADC Development - Issues and Challanges
  • Bioanalytical & Pre-Clinical Development Strategies for ADCs
  • Cancer Antibody Therapeutics
  • Manufacture and Production Strategies for ADC
  • Novel Conjugation Technologies, Payload & Linkers
  • Strategies and Approaches for Development of Specific and Targeted ADCs

Sponsorship and Exhibition Opportunities

Maninderjit Singh, Exhibition Manager
mjsingh@selectbio.com
7696225050

Distinguished Faculty

Ajay Kumar Gupta, Director & Head, Confederation of Indian Industry
Dimiter Dimitrov, Head/Senior Investigator, National Institutes of Health
Preeti Nigam Joshi, INSPIRE Faculty, National Chemical Laboratory
Tulsidas Shrivastav, Professor, National Institute of Health & Family Welfare
Anjali Karande, Professor, Indian Institute of Science
G Praveen Kumar, Professor & Principal, Sahasra Institute of Pharmaceutical Sciences
Jeremy Parker, Project Leader, AstraZeneca
Tapas Das, Scientific Officer, Bhabha Atomic Research Centre
Rajkumar Halder, Scientist E, Translational Health Science and Technology Institute
Madan Katragadda, Senior Principal Scientist, Pfizer
Sanghamitra Bhattacharjee, Senior Scientist, Theramyt Novobiologics Pvt. Ltd
Mark Wright, Site Lead, Piramal Healthcare UK Ltd
Palani Palaniappan, Vice President & Head, Takeda Pharmaceuticals International Co.


Corporate SponsorsWeb SponsorsOffical Journal PartnerNetworking
Drug Discovery WorldU-Networks